Preclinical Evaluation of (203/212)Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer

Targeted radiopharmaceutical therapy (TRT) using α-particle radiation is a promising approach for treating both large and micrometastatic lesions. We developed prostate-specific membrane antigen (PSMA)–targeted low-molecular-weight agents for (212)Pb-based TRT of patients with prostate cancer (PC) b...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Nucl Med
Autores principales: Banerjee, Sangeeta Ray, Minn, Il, Kumar, Vivek, Josefsson, Anders, Lisok, Ala, Brummet, Mary, Chen, Jian, Kiess, Ana P., Baidoo, Kwamena, Brayton, Cory, Mease, Ronnie C., Brechbiel, Martin, Sgouros, George, Hobbs, Robert F., Pomper, Martin G.
Formato: Artigo
Lenguaje:Inglês
Publicado: Society of Nuclear Medicine 2020
Materias:
Theranostics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6954458/
https://ncbi.nlm.nih.gov/pubmed/31253744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.229393
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares